
Peter R Carroll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2231299/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. Journal of Urology, 2022, 207, 127-136.	0.4	7
2	Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database. Prostate Cancer and Prostatic Diseases, 2022, 25, 690-693.	3.9	8
3	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	4.1	3
4	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. European Urology Oncology, 2022, 5, 537-543.	5.4	13
5	Identification of prostate cancer using multiparametric MR imaging characteristics of prostate tissues referenced to whole mount histopathology. Magnetic Resonance Imaging, 2022, 85, 251-261.	1.8	7
6	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
7	Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. Journal of Urology, 2022, 207, 832-840.	0.4	8
8	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.4	3
9	The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. Journal of Urology, 2022, 207, 1001-1009.	0.4	3
10	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large―cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	5.5	10
11	Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score Journal of Clinical Oncology, 2022, 40, 35-35.	1.6	Ο
12	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	2.3	2
13	The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2022, 25, 344-350.	3.9	9
14	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Human Pathology, 2022, 122, 84-91.	2.0	6
15	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	2.8	3
16	Editorial Comment. Journal of Urology, 2022, , 101097JU000000000000249102.	0.4	0
17	Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score Journal of Clinical Oncology, 2022, 40, 5024-5024.	1.6	1
18	Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	1

#	Article	IF	CITATIONS
19	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. European Urology Focus, 2021, 7, 1268-1273.	3.1	6
20	Influence of pelvic lymph node dissection and nodeâ€positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. Prostate, 2021, 81, 102-108.	2.3	6
21	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383.	1.9	93
22	Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology, 2021, 149, 168-173.	1.0	6
23	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 501-508.	6.4	30
24	Editorial Comment. Journal of Urology, 2021, 205, 121-121.	0.4	0
25	The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance—Does Cancer Vanish or Simply Hide?. Journal of Urology, 2021, 205, 109-114.	0.4	2
26	Single-cell analysis of cellular state heterogeneity in human localized prostate cancer Journal of Clinical Oncology, 2021, 39, 254-254.	1.6	0
27	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021, 39, 33-33.	1.6	Ο
28	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. BMC Urology, 2021, 21, 18.	1.4	3
29	Clinical Utility of 4Kscore [®] , ExosomeDxâ,,¢ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. Journal of Urology, 2021, 205, 452-460.	0.4	36
30	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021, 39, 32-32.	1.6	2
31	Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Scientific Reports, 2021, 11, 5040.	3.3	40
32	Editorial Comment. Journal of Urology, 2021, 205, 777-778.	0.4	0
33	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 781.e17-781.e24.	1.6	10
34	Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history. Cancer Causes and Control, 2021, 32, 635-644.	1.8	3
35	Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. International Journal of Molecular Sciences, 2021, 22, 4367.	4.1	62
36	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precision Oncology, 2021, 5, 710-725.	3.0	6

#	Article	IF	CITATIONS
37	SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers, 2021, 13, 2047.	3.7	45
38	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021, 39, 5023-5023.	1.6	1
39	A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021, 39, e17003-e17003.	1.6	0
40	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 2021, 79, 717-721.	1.9	13
41	A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4463-4471.	6.4	9
42	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate, 2021, 81, 1009-1017.	2.3	2
43	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Reply Journal of Urology, 2021, 206, 174-174.	0.4	1
44	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology, 2021, , .	1.0	1
45	Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. Journal of Urology, 2021, 206, 706-714.	0.4	5
46	Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. Urology, 2021, 155, 91-95.	1.0	6
47	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science, 2021, 34, 47-54.	0.4	3
48	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 136-143.	3.9	36
49	Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clinical Genitourinary Cancer, 2020, 18, e21-e27.	1.9	4
50	Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Medicine, 2020, 9, 125-132.	2.8	7
51	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer, 2020, 126, 583-592.	4.1	9
52	MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. American Journal of Roentgenology, 2020, 214, 574-578.	2.2	15
53	The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa044.	2.9	0
54	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	3.0	2

#	Article	IF	CITATIONS
55	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
56	Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. European Urology Oncology, 2020, , .	5.4	7
57	Comparison of biopsy underâ€ s ampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies. Cancer Medicine, 2020, 9, 9611-9619.	2.8	6
58	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e1-793.e11.	1.6	7
59	Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443–51. European Urology, 2020, 78, e110-e111.	1.9	0
60	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. JAMA Oncology, 2020, 6, 1793.	7.1	10
61	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	7.1	30
62	A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. BMC Cancer, 2020, 20, 820.	2.6	14
63	Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate, 2020, 80, 1421-1428.	2.3	1
64	Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Scientific Reports, 2020, 10, 21750.	3.3	34
65	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	5.0	74
66	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	1.6	170
67	Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. European Urology, 2020, 78, 515-517.	1.9	12
68	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. European Urology, 2020, 78, 335-344.	1.9	28
69	Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate, 2020, 80, 653-659.	2.3	17
70	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology, 2020, 296, 76-84.	7.3	207
71	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. JAMA Network Open, 2020, 3, e2031349.	5.9	41
72	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2020, 204, 1216-1221.	0.4	9

#	Article	IF	CITATIONS
73	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2020, 204, 1222-1228.	0.4	30
74	Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR) Journal of Clinical Oncology, 2020, 38, 5501-5501.	1.6	21
75	Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis. Journal of Medical Internet Research, 2020, 22, e19322.	4.3	127
76	18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer Journal of Clinical Oncology, 2020, 38, 300-300.	1.6	0
77	Editorial Comment. Journal of Urology, 2020, 203, 1121-1121.	0.4	0
78	Reply by Authors. Journal of Urology, 2020, 204, 1221-1221.	0.4	0
79	Hematuria Practice Guidelines That Explicitly Consider Harms and Costs. JAMA Internal Medicine, 2019, 179, 1362.	5.1	3
80	Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. European Urology, 2019, 76, 743-751.	1.9	5
81	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. European Urology Oncology, 2019, 2, 685-690.	5.4	21
82	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
83	Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 713-723.	1.5	16
84	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	3.9	22
85	Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. Urology, 2019, 129, 165-171.	1.0	41
86	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
87	Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. American Journal of Men's Health, 2019, 13, 155798831983532.	1.6	2
88	Guidelines should be assessed based on the underlying evidence. Cmaj, 2019, 191, E871-E871.	2.0	0
89	Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1917-1925.	2.5	20
90	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology, 2019, 125, 154-162.	1.0	20

#	Article	IF	CITATIONS
91	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	5.0	35
92	Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. European Urology, 2019, 75, 950-958.	1.9	45
93	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	6.3	142
94	Genomic Prostate Score, PI-RADSâ,,¢ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. Journal of Urology, 2019, 201, 300-307.	0.4	36
95	Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. Journal of Urology, 2019, 202, 90-95.	0.4	16
96	Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. Journal of Urology, 2019, 202, 506-510.	0.4	22
97	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2019, 202, 696-701.	0.4	16
98	A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. Journal of Urology, 2019, 202, 702-709.	0.4	35
99	Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. Journal of Urology, 2019, 202, 689-695.	0.4	10
100	SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. Journal of Urology, 2019, 202, 952-958.	0.4	8
101	A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study. Journal of Medical Internet Research, 2019, 21, e14094.	4.3	7
102	Editorial Comment. Journal of Urology, 2019, 201, 298-299.	0.4	0
103	Reply by Authors. Journal of Urology, 2019, 202, 958-958.	0.4	0
104	Germline testing in those at risk of prostate cancer. Canadian Journal of Urology, 2019, 26, 31-33.	0.0	4
105	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	1.9	30
106	Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. European Urology, 2018, 73, 215-223.	1.9	45
107	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2018, 199, 719-725.	0.4	4
108	Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy. Journal of Urology, 2018, 199, 699-705.	0.4	16

#	Article	IF	CITATIONS
109	Cycling, and Male Sexual and Urinary Function: Results from a Large, Multinational, Cross-Sectional Study. Journal of Urology, 2018, 199, 798-804.	0.4	33
110	Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREâ,,¢). Prostate, 2018, 78, 32-39.	2.3	22
111	Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction. Molecular Imaging, 2018, 17, 153601211881174.	1.4	6
112	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology, 2018, 289, 730-737.	7.3	114
113	A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy. European Urology, 2018, 74, 731-738.	1.9	186
114	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. European Urology, 2018, 74, 668-675.	1.9	34
115	Effect of Oscillation on Perineal Pressure in Cyclists: Implications for Micro-Trauma. Sexual Medicine, 2018, 6, 239-247.	1.6	11
116	USPTF Prostate Cancer Screening Recommendations—A Step in the Right Direction. JAMA Surgery, 2018, 153, 701.	4.3	3
117	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget, 2018, 9, 6550-6561.	1.8	16
118	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11257.	1.0	9
119	Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 329-332.	1.9	8
120	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655.	1.9	190
121	Risk Stratification of Newly Diagnosed Prostate Cancer with GenomicÂPlatforms. Urology Practice, 2017, 4, 322-328.	0.5	Ο
122	Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate International, 2017, 5, 95-103.	2.3	7
123	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	7.1	219
124	Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate, 2017, 77, 425-434.	2.3	4
125	Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. Journal of Urology, 2017, 198, 671-677.	0.4	16
126	Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	3.8	65

#	Article	IF	CITATIONS
127	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
128	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology, 2017, 71, 750-759.	1.9	40
129	Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed wholeâ€mount histopathology as a reference standard. NMR in Biomedicine, 2017, 30, e3796.	2.8	19
130	Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers. Prostate, 2017, 77, 1573-1582.	2.3	8
131	Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 663.e9-663.e14.	1.6	10
132	The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer, 2017, 123, 4574-4582.	4.1	36
133	What is the best way not to treat prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 42-50.	1.6	13
134	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clinical Genitourinary Cancer, 2017, 15, 93-99.	1.9	1
135	18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. Radiology, 2017, 282, 429-436.	7.3	15
136	Magnetic Resonance Imaging–Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 275-281.	1.9	88
137	A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. Journal of Urology, 2017, 197, 369-375.	0.4	19
138	Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiologia Brasileira, 2017, 50, 299-307.	0.7	11
139	Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Research, 2017, 7, 77.	2.5	33
140	Luminal and basal subtyping of prostate cancer Journal of Clinical Oncology, 2017, 35, 3-3.	1.6	2
141	Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS ONE, 2017, 12, e0185535.	2.5	22
142	The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study. JMIR Cancer, 2017, 3, e5.	2.4	35
143	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS) Journal of Clinical Oncology, 2017, 35, 22-22.	1.6	0
144	Luminal and basal subtyping of prostate cancer Journal of Clinical Oncology, 2017, 2017, 3-3.	1.6	0

#	Article	IF	CITATIONS
145	Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy Journal of Clinical Oncology, 2017, 35, 110-110.	1.6	0
146	Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer Journal of Clinical Oncology, 2017, 35, 58-58.	1.6	0
147	Milk and other dairy foods in relation to prostate cancer progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE) Journal of Clinical Oncology, 2017, 35, 168-168.	1.6	1
148	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	2.3	19
149	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.4	43
150	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncology, 2016, 2, 882.	7.1	458
151	Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 727-733.	0.4	4
152	Immediate androgen deprivation: for all or for some?. Lancet Oncology, The, 2016, 17, 683-684.	10.7	3
153	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology, 2016, 96, 116-120.	1.0	11
154	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	10.7	182
155	Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate, 2016, 76, 339-348.	2.3	32
156	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	3.1	60
157	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. Journal of Molecular Diagnostics, 2016, 18, 395-406.	2.8	46
158	Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nature Reviews Urology, 2016, 13, 151-167.	3.8	139
159	New Genetic Markers for Prostate Cancer. Urologic Clinics of North America, 2016, 43, 7-15.	1.8	12
160	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	2.5	19
161	Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?. BJU International, 2015, 116, 713-720.	2.5	13
162	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	2.5	28

#	Article	IF	CITATIONS
163	Patterns of Local Failure following Radiation Therapy for Prostate Cancer. Journal of Urology, 2015, 194, 977-982.	0.4	39
164	A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	2.3	55
165	Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Science Signaling, 2015, 8, ra116.	3.6	37
166	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. European Urology, 2015, 67, 646-648.	1.9	25
167	Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer. Journal of Urology, 2015, 193, 807-811.	0.4	148
168	Current Use of Imaging after Primary Treatment of Prostate Cancer. Journal of Urology, 2015, 194, 98-104.	0.4	4
169	What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?. Journal of Urology, 2015, 194, 615-616.	0.4	1
170	Immediate Versus Delayed Radical Prostatectomy: Updated Outcomes Following Active Surveillance of Prostate Cancer. European Urology, 2015, 68, 458-463.	1.9	49
171	Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA - Journal of the American Medical Association, 2015, 314, 80.	7.4	543
172	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary–Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	1.9	48
173	Bicycle Trauma Injuries and Hospital Admissions in the United States, 1998-2013. JAMA - Journal of the American Medical Association, 2015, 314, 947.	7.4	46
174	Treatment Trends for Prostate Cancer—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1977.	7.4	2
175	Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS ONE, 2014, 9, e89754.	2.5	17
176	miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. PLoS ONE, 2014, 9, e98597.	2.5	41
177	Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU International, 2014, 114, E18-E24.	2.5	43
178	Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-institution Active Surveillance Cohort. Urology, 2014, 83, 33-39.	1.0	13
179	Autologous retro-pubic urethral sling: a novel, quick, intra-operative technique to improve continence after robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 2014, 8, 99-104.	1.8	7
180	Early Salvage Radiotherapy Following Radical Prostatectomy. European Urology, 2014, 65, 1034-1043.	1.9	171

#	Article	IF	CITATIONS
181	Overdiagnosis and Overtreatment of Prostate Cancer. European Urology, 2014, 65, 1046-1055.	1.9	709
182	Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550–60. European Urology, 2014, 66, e117-e118.	1.9	8
183	Impact of Folate Intake on Prostate Cancer Recurrence Following Definitive Therapy: Data from CaPSUREâ,,¢. Journal of Urology, 2014, 191, 971-976.	0.4	17
184	Evolution and Immediate Future of US Screening Guidelines. Urologic Clinics of North America, 2014, 41, 229-235.	1.8	3
185	Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology. Radiotherapy and Oncology, 2014, 110, 303-308.	0.6	39
186	The Ongoing Need for Improved Risk Stratification and Monitoring for Those on Active Surveillance for Early Stage Prostate Cancer. European Urology, 2014, 65, 1032-1033.	1.9	7
187	Age and Baseline Quality of Life at Radical Prostatectomy—Who Has the Most to Lose?. Journal of Urology, 2014, 192, 396-401.	0.4	24
188	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	1.9	553
189	A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer. Urology, 2014, 83, 592-598.	1.0	43
190	Predictors of Pathologic Progression on Biopsy Among Men on Active Surveillance for Localized Prostate Cancer: The Value of the Pattern of Surveillance Biopsies. European Urology, 2014, 66, 337-342.	1.9	56
191	Impact of Androgen Deprivation Therapy on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSUREâ"¢ Registry. Journal of Urology, 2014, 191, 964-970.	0.4	36
192	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. European Urology, 2014, 65, 1171-1177.	1.9	110
193	Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 768-771.	4.9	8
194	Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncology, The, 2013, 14, 1112-1120.	10.7	321
195	The argument for palliative care in prostate cancer. Translational Andrology and Urology, 2013, 2, 278-80.	1.4	6
196	Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Research, 2011, 71, 3889-3895.	0.9	241
197	Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 3532-3533.	4.1	1
198	IL4 Androgen Deprivation Therapy for Prostate Cancer : A US Perspective. Japanese Journal of Urology, 2010, 101, 53.	0.1	0

#	Article	IF	CITATIONS
199	THE IMPACT OF PATIENT ADVOCACY: THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO EXPERIENCE. Journal of Urology, 2004, 172, S58-61; discussion S61-2.	0.4	5
200	Predictors of Secondary Cancer Treatment in Patients Receiving Local Therapy for Prostate Cancer: Data From Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 2002, 168, 530-535.	0.4	88
201	Origin of Urothelial Carcinoma After Renal Transplant Determined by Fluorescence In Situ Hybridization. Journal of Urology, 2002, 167, 2521-2522.	0.4	6
202	Contemporary Trends in Imaging Test Utilization for Prostate Cancer Staging: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 2002, 168, 491-495.	0.4	69
203	IS ANASTOMOTIC BIOPSY NECESSARY BEFORE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY?. Journal of Urology, 2001, 166, 111-115.	0.4	73
204	UNDER STAGING AND UNDER GRADING IN A CONTEMPORARY SERIES OF PATIENTS UNDERGOING RADICAL PROSTATECTOMY: RESULTS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR DATABASE. Journal of Urology, 2001, 165, 851-856.	0.4	154
205	Is it necessary to do staging pelvic lymph node dissection for T1c prostate cancer?. Current Urology Reports, 2001, 2, 237-241.	2.2	4
206	Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magnetic Resonance in Medicine, 2001, 46, 49-57.	3.0	120
207	Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer, 1998, 83, 538-546.	4.1	53
208	Continence mechanism of the ileal neobladder in women: a urodynamics study. World Journal of Urology, 1998, 16, 400-404.	2.2	32
209	LOCALLY RECURRENT PROSTATE TUMORS FOLLOWING EITHER RADIATION THERAPY OR RADICAL PROSTATECTOMY HAVE CHANGES IN KI-67 LABELING INDEX, P53 AND BCL-2 IMMUNOREACTIVITY. Journal of Urology, 1998, 159, 1437-1443.	0.4	81
210	Surgery of the ProstateResnickM.I. and ThompsonI.M.: Surgery of the Prostate. New York: Churchill Livingstone, Inc.1998. , 387 pages Journal of Urology, 1998, 159, 2268-2269.	0.4	0
211	USE OF IMAGING TESTS FOR STAGING NEWLY DIAGNOSED PROSTATE CANCER: TRENDS FROM THE CAPSURE DATABASE. Journal of Urology, 1998, 160, 2102-2106.	0.4	56
212	Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1997, 19, 84-89.	2.8	49
213	A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. , 1996, 78, 1775-1780.		23
214	Chromosome-9 loss detected by fluorescencein situ hybridization in bladder cancer. International Journal of Cancer, 1995, 64, 99-103.	5.1	61
215	Editorial: Prostate Cancer–Many Treatments But Not Enough Answers. Journal of Urology, 1995, 154, 454-455.	0.4	3
216	Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. Journal of Surgical Oncology, 1994, 55, 7-13.	1.7	36

#	Article	IF	CITATIONS
217	Editorial: Laparoscopic Urological Surgery: Differentiating What Should Be Done from What Can Be Done. Journal of Urology, 1994, 151, 1603-1604.	0.4	6
218	The Value of Prostate Specific Antigen and Transrectal Ultrasound Guided Biopsy in Detecting Prostatic Fossa Recurrences Following Radical Prostatectomy. Journal of Urology, 1993, 149, 1024-1028.	0.4	109
219	Pyoderma Gangrenosum Presenting as Fournier's Gangrene. Journal of Urology, 1990, 144, 984-986.	0.4	36
220	Ureteral Obstruction Caused by Vasculitis. Journal of Urology, 1989, 141, 933-935.	0.4	23
221	Renal Trauma: Re-Evaluation of the Indications for Radiographic Assessment. Journal of Urology, 1985, 133, 183-186.	0.4	95
222	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.4	1